How much funding has BE Biopharma raised?

BE Biopharma has raised $356.0M in total funding, most recently a Series C round.

Who are BE Biopharma's investors?

BE Biopharma's investors include ARCH Venture Partners, Atlas Venture, Biomatics Capital Partners, RA Capital Management, Alta Partners, Longwood Fund.

When was BE Biopharma founded?

BE Biopharma was founded in 2020.

Where is BE Biopharma headquartered?

BE Biopharma is headquartered in Cambridge, United States.

What industry is BE Biopharma in?

BE Biopharma operates in Biotech, Healthcare.

How many employees does BE Biopharma have?

BE Biopharma has 51-200 employees.

BE Biopharma

Advancing our science with bold humanity

Cambridge, United States · Founded 2020 · $356.0M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 51–200
Founded: 2020
Business Model: B2B

Website: be.bio
Total Funding: $356.0M
Last Round: $92.0M Series CJan 2025
Rounds: 4

About

Be Biopharma is pioneering Engineered B Cell Medicines (BCMs) to improve the lives of patients living with Hemophilia B and other genetic diseases, cancer, and serious conditions. Founded in October 2020 and headquartered in Cambridge, Massachusetts, the company is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Bristol Myers Squibb, and Takeda Ventures.

Summary

BE Biopharma is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $356.0M in total across 4 rounds, most recently a $92.0M Series C round in Jan 2025. Investors include ARCH Venture Partners, Atlas Venture and Biomatics Capital Partners.